2020년 7월 27일 17:33

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health

Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (s...

2020년 7월 16일 10:06

European Commission approves third nintedanib indication in pulmonary fibrosis[1]

Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyon...

2020년 7월 10일 10:27

Perceived burden of disease is greater in younger people living with COPD, global survey reveals

Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.[1] Findings indicate ...

2020년 7월 8일 08:53

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and g...

2020년 6월 9일 09:24

New consortium EUbOPEN will provide tools to unlock disease biology

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-char...

2020년 6월 1일 09:02

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis[1]

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatm...

2020년 5월 27일 10:57

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and ...

2020년 5월 15일 16:13

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim...

2020년 5월 14일 11:39

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide

Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal di...

2020년 4월 21일 18:10

Boehringer Ingelheim’s Aservo® EquiHaler® wins Red Dot for outstanding design quality

Boehringer Ingelheim is proud to announce that its Aservo® EquiHaler® received a Red Dot Award for product design. Aservo® EquiHaler® is an inhalant therapy licensed for use in horses with severe equine asthma. The Red Dot Award: Product Design is...